Colorcon, Inc. Launches On-Dose Authentication Platform From Applied DNA Sciences
December 23 2019 - 09:30AM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA”), a
leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing
for product authenticity, traceability solutions and nucleic
acid-based biotherapeutic development, announced today that its
partner, Colorcon, a world leader in the development and supply of
film coating systems and excipients, formally launched the On-Dose
Authentication capability to provide track and trace functionality
for supply chain security. The seamless integration of molecular
taggants from Applied DNA Sciences (ADNAS) into an Opadry® fully
formulated film coating system significantly reduces the risks
associated with counterfeit and falsified medications entering the
supply chain.
This first commercial offering is the culmination of extensive
collaboration between Colorcon and ADNAS to help pharmaceutical
companies enhance patient safety and reduce risk by using
intelligent data and analytics gathered from authentication of the
dosage form itself. By better understanding the vulnerabilities of
a complex global supply chain, drug manufacturers can make informed
decisions regarding distribution networks and deploy preventative
measures to address counterfeiting and product diversion
issues.
Dr. Ali Rajabi-Siahboomi, Vice President/Chief Scientific
Officer at Colorcon Inc. says, “With new guidelines from regulators
and accessible technology, on-dose solutions provide a more robust
and reliable means of identifying and deterring counterfeiting,
verifying product authenticity, and ensuring product traceability.
Through extensive research and development, Colorcon has created a
unique coating system to address this global problem.”
Kelly Boyer, General Manager, Film Coatings at Colorcon Inc.
explains, “On-dose authentication technology represents the next
generation in pharmaceutical supply-chain security by providing a
powerful tool for tracking product from plant to patient. By
seamlessly enabling authentication, these digitized coatings
confirm the quality and origin of medicines thereby safeguarding
both patients and brands.”
Colorcon continues to advance technologies and services to meet
industry challenges with innovative solutions. This latest
technology yet again demonstrates Colorcon’s leadership in
responding to the needs of the pharmaceutical industry, bringing
novel solutions that are efficient to deliver with dependable
performance.
About Applied DNA Sciences Applied DNA is a provider of
molecular technologies that enable supply chain security,
anti-counterfeiting and anti-theft technology, product genotyping
and pre-clinical nucleic acid-based therapeutic drug
candidates.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN.
About Colorcon Colorcon is a world leader in the
development, supply and technical support of specialty ingredients;
formulated film coating systems, modified release technologies, and
functional excipients for the pharmaceutical industry. Our
best-in-class products and technologies are complemented by our
extensive application data and value-added services to support all
phases of solid oral dose design, development and manufacture. Our
focus on market issues and technology development has earned
Colorcon an international reputation as a pharmaceutical supplier
of choice. That reputation is based on superior product quality,
unparalleled technical support, extensive regulatory assistance and
reliable supply from multiple locations. Colorcon has 11
manufacturing facilities, 21 technical service laboratories
globally and more than 1200 employees exclusively dedicated to its
customer base.
For more information, visit www.colorcon.com.
Forward-Looking Statements The statements made by Applied DNA in
this press release may be “forward-looking” in nature within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. Forward-looking statements describe
Applied DNA’s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
Applied DNA. Actual results could differ materially from those
projected due to the possibility of a failure to make timely
payment on its outstanding secured convertible notes and resulting
enforcement by noteholders of remedies on collateral which includes
substantially all of Applied DNA’s assets, its history of net
losses, limited financial resources, limited market acceptance,
approval of Applied DNA’s taggant technology by the U.S. Food and
Drug Administration or equivalent foreign regulatory agencies as a
physical-chemical identifier (PCID) for solid oral dosage forms and
various other factors detailed from time to time in Applied DNA’s
SEC reports and filings, including our Annual Report on Form 10-K
filed on December 12, 2019 and other reports we file with the SEC,
which are available at www.sec.gov. Applied DNA undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events, unless
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191223005110/en/
investors: Sanjay M. Hurry, LHA Investor Relations,
212-838-3777, shurry@lhai.com program: Judy Murrah, Chief
Information Officer, 631-240-8800, judy.murrah@adnas.com
web: www.adnas.com twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2023 to Mar 2024